Skip to content

Royan Institute

  Home arrow Baharvand
PDF Print E-mail

Hossein Baharvand, PhD

1- Associate Professor, Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
2- Department of Developmental Biology, University of Science and Culture, ACECR, Tehran, Iran

Aim and interests:
Our mission is to generate insights into the biology of stem cells through basic research and to provide the foundation needed for novel therapies from regenerative medicine. We are trying to provide a comprehensive and coordinated "bench to bedside" approach to regenerative medicine, including a greater understanding of fundamental biology of stem cells, developmental biology, tissue engineering programs, the development of translational research of stem cell therapeutics, and administration of new cell therapies approaches that can restore tissue function to patients.
One of our main priority is to derivate and to maintain embryonic stem cells from mice and humans. Accordingly, we have derived 11 lines of human embryonic stem cells and more than 170 lines of mouse embryonic stem cells from 2002 until now. In recent years, we have focused on the generation of new embryonic stem cell lines by new signaling pathways, induced pluripotent stem cells, the biology of embryonic stem cells and induced pluripotent stem cells, mechanisms of pluripotency, optimization the culture and maintenance of pluripotent stem cells and the scale-up culture of these cells for biomedical applications.
Our second main interest is epigenetic reprogramming, which can be considered the biological breakthrough of the decade. In recent years, there has been an increased interest in the study of induced pluripotent stem cell (iPSC) biology and cell fate conversion because of the potential of iPSC in regenerative medicine, disease modeling, drug discovery and in vitro analysis of development, which have led scientists to enthusiastically embrace this field. Patient specific iPSCs, will give us the chance of genetic correction and functional analysis of these cells in order to study the disease mechanisms, development and disease modeling for drug discovery trials. iPSC technology has provided scientists with patient-derived pluripotent stem cells that can be differentiated towards interesting cells affected by certain diseases. To reach this goal, we have established iPSC lines from some diseases. We have launched some projects to generate safer iPSCs using small molecules, recombinant proteins and synthetic mRNAs. Direct transdifferentiation of terminally differentiated cells and studying cell fate conversion is one of the highest priorities in our research plan.

See publications by Hossein Baharvand in PubMed

Main Menu